Alexander Spira, MD, PhD, FACP

Articles

Treatment for Early-Stage NSCLC: Resection and Adjuvant Radiation Therapy

July 12th 2022

Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.

Molecular Testing in Advanced-Stage NSCLC: Use of Liquid Biopsy

July 5th 2022

Expert oncologists briefly highlight the role of liquid biopsy in the setting of advanced-stage non–small cell lung cancer.

Use of Molecular Profiling in Early-Stage Non–Small Cell Lung Cancer

July 5th 2022

A focused discussion on the use of molecular profiling in early-stage non–small cell lung cancer to inform decisions on adjuvant and neoadjuvant strategies.

Real-World Data and Barriers to Use of Molecular Testing in NSCLC

June 28th 2022

A brief review of real-world data behind molecular profiling in non–small cell lung cancer, followed by a discussion on barriers to testing and uptake.

Optimal Molecular Testing Practices in Non–Small Cell Lung Cancer

June 28th 2022

Expert panelists share insight on molecular testing practices across all subtypes of non–small cell lung cancer to optimally inform treatment decisions.

Dr. Spira on the Potential Role of Adagrasib in NSCLC

June 4th 2022

Alexander I. Spira, MD, PhD, FACP, discusses the adagrasib in patients with non–small cell lung cancer in the phase 2 KRYSTAL-1 trial.

Dr. Spira on the Examination of RTX-240 in a Phase 1 Trial with Solid Tumors

May 6th 2022

Alexander I. Spira, MD, PhD, FACP, discusses the examination of RTX-240 in a phase 1 trial with solid tumors.

Dr. Spira on the Role of Frontline Brigatinib in ALK+ NSCLC

October 4th 2021

Alexander I. Spira, MD, PhD, FACP, discusses the role of frontline brigatinib in ALK-positive non–small cell lung cancer.

Dr. Spira on the Updated Results of the CHRYSALIS Trial in EGFR-Mutant NSCLC

June 22nd 2021

Alexander Spira, MD, PhD, FACP, discusses the updated results of the phase 1 CHRYSALIS trial in EGFR-mutant non–small cell lung cancer.

Dr. Spira on the Challenges of Developing NRG1 Fusion–Directed Therapies in NSCLC

March 3rd 2021

Alexander Spira, MD, PhD, FACP, discusses the challenges of developing targeted therapies for patients with NRG1 fusion–positive non–small cell lung cancer.

Dr. Spira on the Efficacy of Mobocertinib in Metastatic EGFR Exon 20–Mutated NSCLC

March 2nd 2021

Alexander Spira, MD, PhD, FACP, discusses the efficacy of mobocertinib in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.

Dr. Spira on the Rationale of the CHRYSALIS Trial in EGFR-Mutant NSCLC

October 29th 2020

Alexander Spira, MD, PhD, FACP, discusses the rationale of the phase 1 CHRYSALIS trial with amivantamab plus lazertinib in EGFR-mutant non–small cell lung cancer.

Dr. Spira on Atezolizumab in the POPLAR Study for NSCLC

June 2nd 2015

Alexander Spira, MD, PhD, FACP, medical oncology, hematology, Virginia Cancer Specialists, discusses the POPLAR study for non-small cell lung cancer (NSCLC).